SYN - Ziopharm: 13 Failed Programs With 3 More On Deck
In our most recent article, we focused on Iovance (IOVA), a cell therapy company that in our opinion has consistently generated positive data, has developed a commercializable product, and is deploying a de-risked clinical strategy for a clear unmet need. As a result, we saw nearly 100% upside in Iovance’s stock.
In this article, we highlight Ziopharm (ZIOP), a cell therapy company that we think represents the polar opposite to Iovance. Ziopharm’s history is long and littered with suspended and abandoned programs. The company has not shown an ability to develop